EMA's Guido Rasi Receives Leadership Award
EMA's Executive Director, Guido Rasi received the 2014 European Rare Disease Leadership Award 2014.
The European Medicines Agency's Executive Director, Guido Rasi, together with Paola Testori Coggi from the European Commission and Luca Pani from AIFA, have received the 2014 European Rare Disease Leadership Award 2014.
The award has been given by EURORDIS, a non-governmental patient-driven alliance of patient organizations representing 614 rare disease patient groups in 58 countries.
Today, 28 February 2014, is Rare Disease Day, and EURORDIS is planning a series of activities and events, including a television interview in Kenya, a Fun Play Day in Lebanon, an informational awareness-raising campaign in Paraguay, a march in Austria, an auction in Canada, a photo exhibit in China, and a seminar in India. It says thousands of participants from over 80 countries will be involved in the event.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
